Cannabisnewsbreaks Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared To Begin Human Pilot Study #3 Evaluating Dehydratech-Processed Tirzepatide

(MENAFN- Investor Brand Network) Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands.

Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as soon as the first dosing has started, potentially in late October. The company anticipates the final doses will be administered in late November.

To view the full press release, visit

About Lexaria Bioscience Corp.

DehydraTECH(TM) is Lexaria's patented drug delivery formulation and processing platform technology that improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, visit the company's website at
.

NOTE TO INVESTORS : The latest news and updates relating to LEXX are available in the company's newsroom at

About CannabisNewsWire

CannabisNewsWire
(“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text
CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published:
/Disclaimer

CannabisNewsWire
Denver, CO

303.498.7722 Office
[email protected]

CannabisNewsWire is powered by
IBN

MENAFN27092024000224011066ID1108724574